178 related articles for article (PubMed ID: 24659339)
1. Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo.
Li L; Yu C; Ren J; Ye S; Ou W; Wang Y; Yang W; Zhong G; Chen X; Shi H; Su X; Chen L; Zhu W
J Cancer Res Clin Oncol; 2014 Jun; 140(6):895-907. PubMed ID: 24659339
[TBL] [Abstract][Full Text] [Related]
2. Cationic liposome mediated delivery of FUS1 and hIL-12 coexpression plasmid demonstrates enhanced activity against human lung cancer.
Ren J; Yu C; Wu S; Peng F; Jiang Q; Zhang X; Zhong G; Shi H; Chen X; Su X; Luo X; Zhu W; Wei Y
Curr Cancer Drug Targets; 2014; 14(2):167-80. PubMed ID: 24410728
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1.
Ou W; Ye S; Yang W; Wang Y; Ma Q; Yu C; Shi H; Yuan Z; Zhong G; Ren J; Zhu W; Wei Y
Cancer Gene Ther; 2012 Jul; 19(7):489-98. PubMed ID: 22576699
[TBL] [Abstract][Full Text] [Related]
4. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of eukaryotic co-expression plasmid-based STAT3-specific siRNA and LKB1 on ovarian cancer in vitro and in vivo.
Pan Y; Zhang L; Zhang X; Liu R
Oncol Rep; 2015 Feb; 33(2):774-82. PubMed ID: 25420630
[TBL] [Abstract][Full Text] [Related]
6. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
[TBL] [Abstract][Full Text] [Related]
7. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo.
Ito I; Ji L; Tanaka F; Saito Y; Gopalan B; Branch CD; Xu K; Atkinson EN; Bekele BN; Stephens LC; Minna JD; Roth JA; Ramesh R
Cancer Gene Ther; 2004 Nov; 11(11):733-9. PubMed ID: 15486560
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L
Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
[TBL] [Abstract][Full Text] [Related]
10. Additive effects of eukaryotic co‑expression plasmid carrying GRIM‑19 and LKB1 genes on breast cancer in vitro and in vivo.
Zhang W; Shao Y; Du Y; Geng W; Jiang T; Liu H; Zhang D
Mol Med Rep; 2015 Nov; 12(5):7665-72. PubMed ID: 26458553
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy.
Liu M; Jiang L; Fu X; Wang W; Ma J; Tian T; Nan K; Liang X
Cancer Sci; 2018 Oct; 109(10):3055-3067. PubMed ID: 30033530
[TBL] [Abstract][Full Text] [Related]
12. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
13. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
[TBL] [Abstract][Full Text] [Related]
14. CO suppresses prostate cancer cell growth by directly targeting LKB1/AMPK/mTOR pathway in vitro and in vivo.
Yan Y; Du C; Li G; Chen L; Yan Y; Chen G; Hu W; Chang L
Urol Oncol; 2018 Jun; 36(6):312.e1-312.e8. PubMed ID: 29566977
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
[TBL] [Abstract][Full Text] [Related]
16. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.
Whang YM; Park SI; Trenary IA; Egnatchik RA; Fessel JP; Kaufman JM; Carbone DP; Young JD
Oncogene; 2016 Feb; 35(7):856-66. PubMed ID: 26119936
[TBL] [Abstract][Full Text] [Related]
17. [Construction and identification of eukaryotic co-expression plasmid carrying FUS1 and recombinant human IL-12 genes and its effection on apoptosis of A549 cells].
Zhang DM; Yang HS; Zhu W; Feng ZH; Deng HX; Wei YQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 40(4):569-74. PubMed ID: 19764546
[TBL] [Abstract][Full Text] [Related]
18. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
19. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
Della Corte CM; Ciaramella V; Di Mauro C; Castellone MD; Papaccio F; Fasano M; Sasso FC; Martinelli E; Troiani T; De Vita F; Orditura M; Bianco R; Ciardiello F; Morgillo F
Oncotarget; 2016 Jan; 7(4):4265-78. PubMed ID: 26673006
[TBL] [Abstract][Full Text] [Related]
20. Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP.
Ma YP; Yang Y; Zhang S; Chen X; Zhang N; Wang W; Cao ZX; Jiang Y; Zhao X; Wei YQ; Deng HX
J Exp Clin Cancer Res; 2010 May; 29(1):56. PubMed ID: 20497582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
